18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma

PURPOSE This trial was performed to evaluate the impact of adjuvant brachytherapy on local and systemic recurrence rates in patients with soft tissue sarcoma. PATIENTS AND METHODS In a single-institution prospective randomized trial, 164 patients were randomized intraoperatively to receive either adjuvant brachytherapy (BRT) or no further therapy (no BRT) after complete resection of soft tissue sarcomas of the extremity or superficial trunk. The adjuvant radiation was administered by iridium-192 implant, which delivered 42 to 45 Gy over 4 to 6 days. The two study groups had comparable distributions of patient and tumor factors, including age, sex, tumor site, tumor size, and histologic type and grade. RESULTS With a median follow-up time of 76 months, the 5-year actuarial local control rates were 82% and 69% in the BRT and no BRT groups (P = .04), respectively. Patients with high-grade lesions had local control rates of 89% (BRT) and 66% (no BRT) (P = .0025). BRT had no impact on local control in patients with low-grade lesions (P = .49). The 5-year freedom-from-distant-recurrence rates were 83% and 76% in the BRT and no BRT groups (P = .60), respectively. Analysis by histologic grade did not demonstrate an impact of BRT on the development of distant metastasis, despite the improvement in local control noted in patients with high-grade lesions. The 5-year disease-specific survival rates for the BRT and no BRT groups were 84% and 81% (P = .65), respectively, with no impact of BRT regardless of tumor grade. CONCLUSION Adjuvant brachytherapy improves local control after complete resection of soft tissue sarcomas. This improvement in local control is limited to patients with high-grade histopathology. The reduction in local recurrence in patients with high-grade lesions is not associated with a significant reduction in distant metastasis or improvement in disease-specific survival.

Download Full-text

Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time

Journal of Clinical Oncology ◽

10.1200/jco.2003.02.026 ◽

2003 ◽

Vol 21 (14) ◽

pp. 2719-2725 ◽

Cited By ~ 213

Author(s):

Jürgen Weitz ◽

Christina R. Antonescu ◽

Murray F. Brennan

Keyword(s):

Risk Factors ◽

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Current Therapy ◽

Disease Specific Survival ◽

Actuarial Survival ◽

Extremity Soft Tissue Sarcoma ◽

Risk Patients ◽

Disease Specific

Purpose: The objective of this study was to define whether survival of patients with extremity soft tissue sarcoma (STS), stratified for known risk factors, has improved over the last 20 years. Patients and Methods: From January 1982 to December 2001, 1,706 patients with primary and recurrent STS of the extremities were treated at our institution and were prospectively followed. From this cohort, we selected 1,261 patients who underwent complete macroscopic resection and had one of the following histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synovial sarcoma. Median follow-up was 55 months. Patient, tumor, and treatment factors were analyzed as prognostic factors. Results: The 5-year disease-specific actuarial survival was 79% (78% for patients treated from 1982 to 1986, 79% for patients treated from 1986 to 1991, 79% for patients treated from 1992 to 1996, and 85% for patients treated from 1997 to 2001; P = not significant). For high-risk patients (high-grade, > 10 cm, deep tumors; n = 247), 5-year disease-specific survival was 51% (50% for patients treated from 1982 to 1986, 45% for patients treated from 1986 to 1991, 52% for patients treated from 1992 to 1996, and 61% for patients treated from 1997 to 2001; P = not significant). Tumor depth, size, grade, microscopic margin status, patient age, presentation status (primary tumor versus local recurrence), location (proximal versus distal), and certain histopathologic subtypes were significant prognostic factors for disease-specific survival on multivariate analysis; however, time period of treatment was not. Conclusion: Prognosis of patients with extremity STS, stratified for known risk factors, has not improved over the last 20 years, indicating that current therapy has reached the limits of efficacy.

Download Full-text

Follow-up after primary treatment of soft tissue sarcoma of extremities: Impact of frequency of follow-up imaging on disease-specific survival

Journal of Surgical Oncology ◽

10.1002/jso.23060 ◽

2012 ◽

Vol 106 (2) ◽

pp. 155-161 ◽

Cited By ~ 14

Author(s):

Yi-Sheng Chou ◽

Chun-Yu Liu ◽

Wei-Ming Chen ◽

Tain-Hsiung Chen ◽

Paul Chih-Hsueh Chen ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Primary Treatment ◽

Disease Specific Survival ◽

Disease Specific

Download Full-text

Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.

Journal of Clinical Oncology ◽

10.1200/jco.1997.15.2.646 ◽

1997 ◽

Vol 15 (2) ◽

pp. 646-652 ◽

Cited By ~ 176

Author(s):

J J Lewis ◽

D Leung ◽

M Heslin ◽

J M Woodruff ◽

M F Brennan

Keyword(s):

Soft Tissue ◽

Local Recurrence ◽

Soft Tissue Sarcoma ◽

Distant Metastasis ◽

High Grade ◽

Disease Specific Survival ◽

Primary Tumors ◽

Poor Prognostic Factor ◽

Extremity Soft Tissue Sarcoma ◽

Disease Specific

PURPOSE The aim of this study was to analyze local recurrence in a large cohort of prospectively followed patients with primary extremity soft tissue sarcoma. In particular, we analyzed the correlation of local recurrence with subsequent metastasis and disease-specific survival. PATIENTS AND METHODS Patients who underwent treatment for primary extremity soft tissue sarcoma from July 1982 through July 1995 at Memorial Sloan-Kettering Cancer Center were the subject of this study. Local recurrence, distant metastasis, and disease-specific survival were used as end points of the study. The influence of local recurrence on subsequent distant metastasis and disease-specific survival were examined using the Cox proportional hazards model. RESULTS We treated 911 patients, of whom 297 (33%) developed recurrent disease. Local recurrence occurred in 116 patients (13%), metastasis in 167 (18%), and synchronous local recurrence and metastasis in 13 (2%). Of 116 patients who developed local recurrence, 38 subsequently developed metastasis and 34 died of disease. Metastasis after local recurrence was predicted in patients with initial high-grade (P = .005; risk = 3.5) or deep (P = .02; risk = 2.9) tumors. Tumor mortality after local recurrence was predicted in patients with initial high-grade (P = .007; risk = 3.7) or large (> 5 cm; P = .01; risk = 3.2) primary tumors. DISCUSSION These findings suggest that there is a strong association of local recurrence with the development of subsequent metastasis and tumor mortality, and that local recurrence is a poor prognostic factor. It would seem prudent to consider patients who develop local recurrence and have high-grade tumors as being at high risk for systemic disease and therefore eligible for investigational adjuvant systemic therapy.

Download Full-text

The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0219215 ◽

2019 ◽

Vol 14 (7) ◽

pp. e0219215 ◽

Cited By ~ 6

Author(s):

Xiaolin Wang ◽

Song Liu ◽

Xiaoli Zhao ◽

Erhu Fang ◽

Xiang Zhao

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Meta Analysis ◽

Prognostic Indicator ◽

Disease Specific Survival ◽

C Reactive Protein ◽

Reactive Protein ◽

Disease Specific

Download Full-text

Soft Tissue Sarcoma

10.2310/surg.2042 ◽

2020 ◽

Author(s):

Aimee M. Crago ◽

Samuel Singer

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Tumor Staging ◽

Treatment Algorithm ◽

Tumor Location ◽

Disease Specific Survival ◽

Cross Sectional ◽

Clinical Prognosis ◽

Histologic Subtype ◽

Disease Specific

Soft tissue sarcoma (STS) refers to a rare group of cancers that develop from mesenchymal cells and their progenitors. Histologic subtype, in conjunction with tumor location and size, largely defines the biologic behavior of a given lesion and the associated clinical prognosis in these cancers. The diverse characteristics of these tumors means that their treatment is similarly complex. The etiology, tumor staging and prognosis, evaluation, and treatment of STS are discussed in this review, with an aim to present an algorithm for patient evaluation and treatment while highlighting common indications for diverging from this strategy as dictated by disease subtype and location. Figures show the histologic distribution of primary STS diagnosed in the extremity and retroperitoneum and intra-abdominal compartments; disease-specific survival for primary extremity and retroperitoneal and intra-abdominal tumors stratified by histologic subtype; local recurrence in primary extremity STS stratified by histologic subtype; disease-specific survival according to American Joint Committee on Cancer (AJCC) TNGM stage; a postoperative nomogram for prediction of sarcoma-specific death at 12 years postresection for patients with STS; representative cross-sectional images of an atypical lipomatous tumor, a myxofibrosarcoma, and a desmoid tumor; a treatment algorithm for STS of the extremity; a magnetic resonance image and intraoperative photographs showing a mixoid liposarcoma of the posterior thigh; and computed tomography showing a retroperitoneal dedifferentiated liposarcoma and a photograph of the surgical bed following resection. This review contains 10 figures, 12 tables, and 49 references. Keywords: Sarcoma, soft tissue, cancer, myxofibrosarcoma, leiomyosarcoma, liposarcoma, gastrointestinal stromal tumor, rhabdomyosarcoma,

Download Full-text

Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study

EJNMMI Research ◽

10.1186/s13550-018-0397-1 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 1

Author(s):

Marc G. Stevenson ◽

Lukas B. Been ◽

Harald J. Hoekstra ◽

Albert J. H. Suurmeijer ◽

Ronald Boellaard ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Fdg Pet ◽

Ct Scans ◽

Volume Of Interest ◽

Extremity Soft Tissue Sarcoma ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

Sarcoma Treatment

Download Full-text

Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group

Cancers ◽

10.3390/cancers11060790 ◽

2019 ◽

Vol 11 (6) ◽

pp. 790 ◽

Cited By ~ 5

Author(s):

Christos Sachpekidis ◽

Ioannis Karampinis ◽

Jens Jakob ◽

Bernd Kasper ◽

Kai Nowak ◽

...

Keyword(s):

High Risk ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Kinetic Analysis ◽

Quantitative Evaluation ◽

Fdg Pet ◽

Standardized Uptake Value ◽

Pet Ct ◽

18F Fdg ◽

Regression Grade

The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we evaluate the potential role of kinetic analysis of fludeoxyglucose F-18 (18F-FDG) data derived from the application of dynamic positron emission tomography/computed tomography (PET/CT) in response assessment to pazopanib of STS patients scheduled for surgical resection. Sixteen STS patients treated with pazopanib as neoadjuvant therapy before surgery were enrolled in the analysis. All patients underwent dynamic PET/CT prior to and after pazopanib treatment. Data analysis consisted of visual (qualitative) analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18F-FDG PET data, based on two-tissue compartment modeling. Resection specimens were histopathologically assessed and the percentage of regression grade was recorded in 14/16 patients. Time to tumor relapse/progression was also calculated. In the follow-up, 12/16 patients (75%) were alive without relapse, while four patients (25%) relapsed, among them one patient died. Median histopathological regression was 20% (mean 26%, range 5–70%). The studied population was dichotomized using a histopathological regression grade of 20% as cut-off. Based on this threshold, 10/14 patients (71%) showed partial remission (PR), while stable disease (SD) was seen in the rest 4 evaluable patients (29%). Semi-quantitative evaluation showed no statistically significant change in the widely used PET parameters, SUVaverage and SUVmax. On the other hand, 18F-FDG kinetic analysis revealed a significant decrease in the perfusion-related parameter K1, which reflects the carrier-mediated transport of 18F-FDG from plasma to tumor. This decrease can be considered as a marker in response to pazopanib in STS and could be due to the anti-angiogenic effect of the therapeutic agent.

Download Full-text

Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma

Current Oncology ◽

10.3747/co.v17i6.538 ◽

2010 ◽

Vol 17 (6) ◽

Cited By ~ 9

Author(s):

D. Roberge ◽

M. Hickeson ◽

M. Charest ◽

R.E. Turcotte

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Pet Ct ◽

Fluorodeoxyglucose Pet

Download Full-text